Need help? Order a test

What do immunophenotype tests show?

The comparative genetic hybridisation (CGH) test provides information about genetic abnormalities present in tumour cells that can be associated with tumours. This test is relatively new and we do not yet provide it at RGCC.

Am I more likely to find the cause of a mutation if I combine both the ChemoSNiP for genomic DNA expression and the Onconomics test?

The Onconomics and Onconomics Plus tests provide information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient.

ChemoSNiP tests for single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments with chemicals, drugs and other agents. This test cannot be used for gene expression analysis.

Is ChemoSNiP a blood test or a buccal swab? How do I collect the sample?

If you only need to order the ChemoSNiP test on its own, a swab is suitable. However if you wish to order other tests in addition to the ChemoSNiP, a patient’s DNA will be isolated from their blood. In this case, a blood sample is sufficient for both tests, so there is no need for a swab.

Does the ChemoSNiP test examine the cause of mutation?

The ChemoSNiP test provides information about DNA mutations that can affect how humans develop cancer or respond to anti-cancer drugs and treatments.

Which test focuses on the efficacy of therapeutic agents against an individual patient’s cancer?

The ChemoSNiP test can be used to predict whether a patient will have a good or bad response to a drug, or no response at all.

Can the Immune-Frame test tell if a patient’s immune system is suppressed as a result of cancer, or if a suppressed immune system caused the cancer?

The Immune-Frame test focuses on the status of a patient’s immune system, based on their cellular markers and the level of cytokine proteins in the test sample.

Which test focuses on the status of the immune system and immunity?

The Immune-Frame test focuses on the status of a patient’s immune system.

Which tests are recommended for follow up and patient monitoring?

Oncocount, Oncotrace or Oncotrail tests can be used to follow up and monitor specific types of tumours.

Which tests are recommended to identify active substances and drugs that work against a tumour?

We recommend the Onconomics or Onconomics Plus tests.

Which test is appropriate for gene expression?

The Onconomics and Onconomics Plus tests look for the expression of genes that are linked with the effect of specific drugs on the cancer cells in a single patient.

Is it possible to test for circulating tumour cells in a tissue sample?

We calculate the number of circulating tumour cells from the total amount of blood cells, expressed as the volume of circulating tumour cells per millilitre of blood. This cannot be calculated from a tissue sample. To conduct a circulating tumour cell test a blood sample must be provided.

An exception is brain tumours, as these cancer cells cannot be detected in the blood.

Can the circulating tumour cell test be done during chemotherapy treatment?

A patient has to wait seven days after chemotherapy treatment before taking the RGCC circulating tumour cell test.

Didn’t get an answer to your query? Get in touch with your local RGCC office

Get in touch

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more